Immix Biopharma (IMMX) Interest & Investment Income (2023 - 2026)
Immix Biopharma (IMMX) posted Interest & Investment Income of $717168.0 for Q1 2026, up 230.93% sequentially from $216712.0 in Q4 2025, and up 377.41% YoY from $150219.0 in Q1 2025.
Immix Biopharma (IMMX) Interest & Investment Income (2023 - 2026) Analysis & Trends
Immix Biopharma has reported Interest & Investment Income for 4 years, with the latest figure at $717168.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 377.41% year-over-year to $717168.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 24.77% YoY) and the FY2025 annual result came in at $555526.0, down 45.4% from the prior year.
- Interest & Investment Income rose to $717168.0 in Q1 2026 per IMMX's latest filing, from $216712.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $717168.0 in Q1 2026 and troughed at $27892.0 in Q1 2023.
- A 4-year average of $220158.0 and a median of $186691.0 in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income surged 860.52% in 2024, then sank 67.06% in 2025.
- Over 4 years, Interest & Investment Income stood at $228575.0 in 2023, then decreased by 18.69% to $185851.0 in 2024, then gained by 16.61% to $216712.0 in 2025, then jumped by 230.93% to $717168.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $717168.0, $216712.0, and $84539.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 913,663.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 913,663.00 |
| Mar 31, 2026 | 717,168.00 |
| Dec 31, 2025 | 216,712.00 |
| Sep 30, 2025 | 84,539.00 |
| Jun 30, 2025 | 104,056.00 |
| Mar 31, 2025 | 150,219.00 |
| Dec 31, 2024 | 185,851.00 |
| Sep 30, 2024 | 256,680.00 |
| Jun 30, 2024 | 306,915.00 |
| Mar 31, 2024 | 267,908.00 |
| Dec 31, 2023 | 228,575.00 |
| Sep 30, 2023 | 186,691.00 |
| Jun 30, 2023 | 128,848.00 |
| Mar 31, 2023 | 27,892.00 |